Trial Profile
The Efficacy and Safety of Apatinib Combined With Etoposide in Advanced Non-small Cell Lung Cancer Patients Failed to Previous at Least 2rd Line Treatments
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Apr 2016 New trial record